Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from 
| INTRODUCTION
Management of dysglycaemia in type 2 diabetes (T2D) has two major goals: correction of chronic hyperglycaemia and reduction of glucose variability, both of which are associated with the development of diabetes-related chronic complications. 1 Glycaemic control is usually assessed using glycated haemoglobin (HbA1c) levels. This measure, however, only reflects the average blood glucose levels (fasting, pre-meal, and postprandial) over the 1 to 3 months prior to testing, and gives little indication of daily fluctuations in blood glucose. 2 Patients with similar HbA1c values can have markedly different daily glucose profiles, with differences in the number and magnitude of glycaemic excursions; even patients with optimum
HbA1c levels can have significant variations in blood glucose levels and postprandial hyperglycaemia. 3 Glycaemic variability (GV) is the term generally used to define intra-day or day-to-day variability in blood glucose levels and includes both periods of hyper-and hypoglycaemia. 1 Studies suggest that it is GV, particularly with excursions into the hyperglycaemic range, rather than chronic sustained hyperglycaemia, that has the greater role in promoting these complications. 1 Risk-based GV measures have also been associated with an increase in the frequency and severity of hypoglycaemia. 2, 4 Given these findings, GV is an emerging consideration in the management of patients with T2D.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) complement the effects of basal insulin by potentiating endogenous insulin responses to hyperglycaemic excursions, suppressing elevated glucagon secretion, promoting satiety, and (for some agents) slowing gastric emptying, therefore blunting postprandial hyperglycaemia. 5 GLP-1RA therapy has been shown to improve HbA1c levels, with a low incidence of hypoglycaemia, 6 and to decrease postprandial glucose (PPG) excursions. 7 Although this profile suggests that GLP-1RAs will decrease GV, there are currently few studies assessing the direct impact of GLP-1RAs on GV in patients with T2D.
Lixisenatide (LIXI) is a once-daily short-acting GLP-1RA that has been found to improve both HbA1c levels and postprandial hyperglycaemia when used in combination with basal insulin, with or without oral antidiabetic drugs (OADs). [8] [9] [10] The objective of the present pooled analysis of patient-level data from three phase III clinical trials was to evaluate the impact of LIXI on GV vs placebo as add-on therapy to basal insulin in patients with T2D.
2 | METHODS
| Study design and patients
Analysis was conducted using pooled patient-level data from three 24-week, randomized, placebo-controlled, phase III, multicentre clini-
GetGoal-Duo1 (NCT00975286), 9 and GetGoal-L-Asia (NCT00866658), 10 the full details of which have been published elsewhere. [8] [9] [10] Each trial evaluated the efficacy and safety of adding LIXI (taken before breakfast) or placebo to basal insulin or basal insulin together with OADs among patients with T2D, baseline HbA1c 7.0% to 10.0% and duration of diabetes ≥1 year. Patient baseline demographics and clinical characteristics across studies are shown in Table S1 .
Patients included in the pooled analysis were the modified intention-to-treat (mITT) population, which included adult patients with baseline HbA1c 7.0% to 10.0%, and duration of diabetes ≥1 year who received at least 1 dose of double-blind study drug from the 3 trials and had both baseline and endpoint HbA1c measurements. Table S2 .
| Study measures
Efficacy was measured using the change in GV values for the LIXI vs placebo cohorts over the 24-week study period.
Endpoints included the percentage of patients achieving HbA1c
<7.0% and composite endpoints; HbA1c <7.0% without symptomatic hypoglycaemia; HbA1c <7.0% without severe hypoglycaemia; HbA1c 
| Statistical analyses
Clinical characteristics and patient demographics were reported using descriptive statistics. Continuous variables were analysed using analysis of variance, and categorical variables were analysed using chisquared tests. Paired t-tests were used for comparison of baseline and endpoint measurements. Partial correlations, accounting for treatment group assignment, were used to test correlations between baseline GV measurements, patient characteristics, and study outcomes. All descriptive statistical analyses were carried out using SAS version 9.2.
| RESULTS
The pooled dataset (N = 1198) included 665 patients from LIXI treatment arms and 533 patients from placebo arms. Patient demographics and clinical characteristics at baseline are shown in Table S3 .
There were no significant differences at baseline between LIXI and placebo in measurements of GV except for AUC-F, which was lower in the placebo group (mean 41.67 vs 35.95 mmol/L × h, respectively; P = .036 [ Table 1 ]). GV was significantly reduced from baseline to week 24 in the LIXI group compared with the placebo group, irrespective of the measure used. This reduction in GV was primarily associated with a significant reduction in HBGI in the LIXI group; GV fell from an HBGI of 10.63 (representing a high risk for hyperglycaemia) to 6.99 (representing a moderate risk for hyperglycaemia). 4 LBGI was unchanged from baseline to week 24 in both groups (0.41 and 0.44 at baseline and week 24, respectively, in the LIXI group; 0.38 and 0.38 at baseline and week 24, respectively, in the placebo group), representing an overall low risk for hypoglycaemia. 4 Higher baseline GV measures were found to correlate with older age, a longer T2D duration, lower body mass index (BMI), and higher baseline PPG and HbA1c levels (Table 2A) . Higher baseline GV measures were also correlated with higher week 24 PPG and week 24 HbA1c levels, a greater PPG reduction, and higher rates of symptomatic hypoglycaemia during follow-up (Table 2B) .
Patients in the LIXI group also experienced a greater mean (s. (Table S4 ).
The overall mean change (s.d.) in the 2-hour post-breakfast SMPG value from baseline to week 24 was significantly greater with LIXI than with placebo; mean change (s.d.) was −2.86 (4.52) mmol/L in the LIXI group vs −0.06 (3.78) mmol/L in the placebo group (P < .0001; Figure S1 ). The LIXI group showed a significantly greater decrease in SMPG levels from baseline to endpoint at 2 hours after breakfast, lunch, and dinner, as well as before lunch and bedtime compared with the placebo group (Table S5) .
| DISCUSSION
The present analysis showed that LIXI added to basal insulin with or without OADs significantly reduced GV and PPG excursions com- Data are mean (s.d.).
1
Comparison LIXI change vs placebo change.
While both fasting plasma glucose (FPG) and PPG levels contribute to glycaemic control, their relative influence on glycaemic exposure as estimated by HbA1c varies; PPG levels may be a more important contributor to HbA1c levels than FPG, particularly in patients with better glycaemic control. 11 In the patient population described in the present study, LIXI had a significant impact on PPG excursions at all 3 meals, as well as beneficial effects on both GV and HbA1c. These findings are clinically important as both GV and PPG have been reported as independent risk factors for cardiovascular disease that are predictive of cardiovascular events and all-cause mortality in patients with T2D. 12 In addition, GV has been associated with additional complications, such as diabetic peripheral neuropathy and stroke. 13, 14 This re-analysis suggests that therapy with LIXI in patients with T2D managed with basal insulin offers an effective strategy that reduces GV as well as HbA1c level. This could potentially be beneficial in the management of patients with T2D and builds on a preexisting body of knowledge. 15 In addition, although patients with T2D are a highly heterogeneous population, the higher incidence of GV observed in older patients, those with a longer duration of diabetes, and those with a lower body weight suggests that treatment with an agent which can reduce GV might be of benefit in some of these high-risk patients.
Overall a significant reduction in GV and PPG excursions com- 
